Compass Therapeutics' core focus lies in the development of innovative antibody-based therapeutics for oncology. This segment encompasses the research and development of bispecific and monoclonal antibodies designed to target various cancer types. Key activities include preclinical studies, Phase I and Phase II clinical trials, and strategic collaborations with pharmaceutical companies like Merck to evaluate combination therapies. The company's pipeline includes CTX-009, CTX-471, and CTX-8371, targeting cancers such as biliary tract, colorectal, ovarian, and small cell lung cancer. The goal is to improve patient outcomes by providing targeted treatments that enhance the immune system's ability to fight cancer cells. Future opportunities include expanding the pipeline with novel antibody constructs and exploring new therapeutic targets.